Understanding Advanced Prostate Cancer

/Understanding Advanced Prostate Cancer

Some Factors That Might Be Predictors of the Duration of Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer

Being able to make better decisions about drug sequencing and combinations has become one of the current hot topics in prostate cancer research. Given that we have a number of newer drugs to use this is an important clinical issue as we make important treatment decisions. Making these clinical decisions is tough.  The fact is that prostate cancer is a very heterogeneous disease and so  drug  responses are not consistent. Compounded by the fact that none of our treatments are effective for an extended time period knowing how to accurately predict drug response is vital. One  example of research dealing [...]

Flawed Study Shows A Sharp Rise in Advanced Prostate Cancer

Yesterday’s post described research performed at Northwestern University that found a sharp increase in the number of men diagnosed with advanced aggressive prostate cancer between 2004 and 2013. The research interpretation raised the possibility that the United States Preventive Task Force (USPTF) decision to recommend against the use of the PSA test for prostate cancer screening was to blame for this high increase of aggressive disease. A number of news media pick up the story as well as this blog. Additional scientific commentary has questioned the research techniques used to draw this conclusion. According the American Cancer Society the study [...]

Reporting A Concerning Increase In The Number Of Men Diagnosed With Advanced Prostate Cancer

According to information from a published report from the Tuesday, July 19, 2016 edition of HealthDay News, there has been an explosion of new cases of advanced prostate cancer in the United States. They reported on a study using data on nearly 800,000 men listed in the National Cancer Data Base who had been diagnosed with prostate cancer between 2004 and 2013.   They concluded that new cases of advanced prostate cancer have skyrocketed by 72 percent in the past decade. They reported that the biggest increase was in the age group of men between 55 to 69 years. They point [...]

Abiraterone And Enzalutamide Effect Cognitive Impairment and Depression in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported depression and a trend towards an increase in cognitive impairment with ENZA as compared to ABI. If you experience any of these symptoms you should discuss them with your doctor. Don't suffer in silence. J Clin Oncol 34, 2016 (suppl; abstr 5059); Parimi, Eigl, Sunderland, [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー